MarketScreener Homepage > Equities > FIRST NORTH STOCKHOLM > Biovica International AB (publ) BIOVIC B SE0008613731

Report

Delayed FIRST NORTH STOCKHOLM - 10/21 11:29:57 am
35.1	SEK		-3.57%

09/25

BIOVICA INTERNATIONAL : completes 510(k) submission for DiviTum®TKa to the FDA

08/27

BIOVICA INTERNATIONAL : Bulletin from the annual general meeting in Biovica

08/27

BIOVICA Q1 INTERIM REPORT : May-July 2020/2021

Summary

Quotes 5-day view Delayed Quote.

Delayed First North Stockholm

10/15/2020	10/16/2020	10/19/2020	10/20/2020	10/21/2020	Date
37.3(c)	37.2(c)	37(c)	36.4(c)	35.1	Last
46 890	21 985	39 078	64 607	92 725	Volume
-4.36%	-0.27%	-0.54%	-1.62%	-3.57%	Change

More quotes

Financials

Sales 2021	19,5 M 2,24 M 2,24 M
Net income 2021	-32,5 M -3,73 M -3,73 M
Net cash position 2021	6,50 M 0,75 M 0,75 M
P/E ratio 2021	-25,3x
Yield 2021	-

Sales 2022	45,5 M 5,22 M 5,22 M
Net income 2022	-17,0 M -1,95 M -1,95 M
Net Debt 2022	18,0 M 2,07 M 2,07 M
P/E ratio 2022	-48,1x
Yield 2022	-

Capitalization	992 M 114 M 114 M
EV / Sales 2021	50,6x
EV / Sales 2022	22,2x
Nbr of Employees	21
Free-Float	70,3%

More Financials

Company

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates...

Sector

Biotechnology & Medical Research

Calendar

More about the company

Notations Surperformance© of Biovica International AB (publ)

Trading Rating :

Investor Rating :

More Ratings

All news about BIOVICA INTERNATIONAL AB (PUBL)

09/25	BIOVICA INTERNATIONAL : completes 510(k) submission for DiviTum®TKa to the FDA	AQ
08/27	BIOVICA INTERNATIONAL : Bulletin from the annual general meeting in Biovica	AQ
08/27	BIOVICA Q1 INTERIM REPORT : May-July 2020/2021	AQ
08/26	BIOVICA INTERNATIONAL : carries out a directed share issue of Class B shares and..	AQ
08/26	BIOVICA INTERNATIONAL : intends to carry out a directed share issue of Class B s..	AQ
08/26	BIOVICA INTERNATIONAL : successfully completes clinical validation for DiviTum® ..	AQ
07/22	BIOVICA INTERNATIONAL PUBL : Notice to AGM for Biovica International AB	AQ
06/30	BIOVICA INTERNATIONAL AB : – Annual Report for the fiscal year 2019/2020 p..	AQ
06/17	BIOVICA INTERNATIONAL PUBL : completes analytical validation as part of FDA appl..	AQ
06/05	Biovica Year-end Report for 2019/2020	AQ
05/22	BIOVICA INTERNATIONAL PUBL : DiviTum® acknowledged in ASCO educational book	AQ
05/11	BIOVICA INTERNATIONAL PUBL : DiviTum® and TK activity acknowledged in highly ren..	AQ
05/11	BIOVICA INTERNATIONAL PUBL : provides market share target at today's Capital Mar..	AQ
05/06	REMINDER : Biovica invites to virtual Capital Markets Day 11 May	AQ
05/06	REMINDER : Biovica invites to virtual Capital Markets Day 11 May	AQ

More news

News in other languages on BIOVICA INTERNATIONAL AB (PUBL)

- No features available -

More news

Chart BIOVICA INTERNATIONAL AB (PUBL)

Duration : Period :

Biovica International AB (publ) Technical Analysis Chart | MarketScreener

Full-screen chart

Income Statement Evolution

More Financials

Consensus

Mean consensus	-
Number of Analysts	2
Average target price	31,00 SEK
Last Close Price	35,10 SEK
Spread / Highest target	-11,7%
Spread / Average Target	-11,7%
Spread / Lowest Target	-11,7%

Consensus

EPS Revisions

More Estimates Revisions

Managers

Name	Title
Anders Rylander	Chief Executive Officer & Director
Lars Erik Holmqvist	Chairman
Adam Germunder	Operations Director
Cecilia Driving	CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist	Director-Clinical Development

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

BIOVICA INTERNATIONAL AB (PUBL)	208.47%	118



EXACT SCIENCES CORPORATION	15.85%	15 470
GUARDANT HEALTH, INC.	30.43%	10 153
BGI GENOMICS CO., LTD.	106.55%	8 593
ADAPTIVE BIOTECHNOLOGIES CORPORATION	61.20%	6 549
SEEGENE INC	--.--%	6 228

More Results